Skip to main content

Table 3 Summary of local control after stereotactic body radiotherapy for liver tumor

From: Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients

First author

Ref.

Target

Year

Case no.

Total RT dose

Fr no.

LC

Timing of LC

Blomgren H

[30]

HCC

1995

20

15-45 Gy

1-5

80%

1.5-38 mo

Tse RV

[26]

HCC & IHC

2008

41

36 Gy

6

65%

12 mo

Cardenes HR

[31]

HCC

2010

17

36-48 Gy

3

100%

10-42 mo

Kwon JH

[32]

HCC

2010

42

30-39 Gy

3

68%

36 mo

Louis C

[33]

HCC

2010

25

45 Gy

3

95%

24 mo

Seo YS

[34]

HCC

2010

38

33-57 Gy

3-4

66%

24 mo

Andolino DL

[28]

HCC

2011

60

40 Gy, 44 Gy

5

90%

24 mo

3

Kang JK

[29]

HCC

2012

50

42-60 Gy

3

95%

24 mo

Takeda A

[21]

HCC

2013

63

35-40 Gy

5

92%

36 mo

Herfarth KK

[10]

ML

2001

37

14-26 Gy

NA

78%

5.7 mo

Wada H

[11]

ML

2004

34

45 Gy

3

86%

12 mo

Kavanagh BD

[12]

ML

2006

36

60 Gy

3

93%

18 mo

Hoyer M

[13]

ML

2006

64

45 Gy

3

63%

24 mo

Katz AW

[14]

ML

2007

69

30-55 Gy

NA

57%

20 mo

Lee MT

[16]

ML

2009

68

27.7-60 Gy

6

71%

12 mo

Rusthoven KE

[17]

ML

2009

47

36-60 Gy

3

92%

24 mo

Rule W

[18]

ML

2011

27

30 Gy,

3

56%

24 mo

50 Gy,

5

89%

60 Gy

5

100%

Chang DT

[19]

ML

2011

65

46-52 Gy

3

90%

12 mo

Fumagalli I

[20]

ML

2012

90

15 Gy

3

66%

24 mo

  1. Abberiviation: HCC hepatocellular carcinoma, IHC intrahepatic cholangiocarcinoma, ML metastatic liver tumor, RT radiotherapy, Fr = fractions, LC = local control, mo months.